The government should alleviate companies’ post-marketing regulatory burdens for intractable disease treatments if it is to encourage their development, a representative of the Japan Pharmaceutical Manufacturers Association (JPMA) told a health ministry panel on April 21. Osamu Inagaki, head of…
To read the full story
Related Article
- AMED Chief Envisages Tapping Private Funds to Fuel R&D
April 22, 2015
REGULATORY
- Pharma Urges Pricing Rewards to Bolster Japan’s Drug Discovery Strength
September 24, 2026
- New Digital Minister Furukawa Pledges Push for Healthy Longevity
September 24, 2026
- MHLW Eyes Higher Long-Term Care Premiums for Wealthier Seniors
September 24, 2026
- Nippon Ishin’s Urano Named Senior Vice Health Minister in Takaichi Cabinet
September 24, 2026
- Ueno Vows to Advance Drug Innovation, Advanced Medicine in 2nd Term
September 24, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





